Forte Biosciences (FBRX) Non-Current Deffered Revenue (2016 - 2019)

Forte Biosciences (FBRX) has 4 years of Non-Current Deffered Revenue data on file, last reported at -$2.3 million in Q1 2019.

• Non-Current Deffered Revenue for Q1 2019 came in at -$2.3 million, down 8614.81% year-over-year; the trailing twelve-month figure through Mar 2019 was -$2.3 million (down 8614.81% YoY), and the FY2018 annual result was $2.2 million, up 6013.89% from the prior year.
• Non-Current Deffered Revenue eased to -$2.3 million in Q1 2019 per FBRX's latest filing, from $2.2 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $2.2 million in Q4 2018 and troughed at -$2.3 million in Q1 2019.
• A 4-year average of $21300.0 and a median of $38500.0 in 2017 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2018 and 2019: Non-Current Deffered Revenue surged 6013.89% in 2018, then sank 8614.81% in 2019.
• A 4-year view of Non-Current Deffered Revenue shows it stood at $68000.0 in 2016, then slumped by 47.06% to $36000.0 in 2017, then surged by 6013.89% to $2.2 million in 2018, then tumbled by 204.45% to -$2.3 million in 2019.
• Business Quant data shows FBRX's Non-Current Deffered Revenue at -$2.3 million in Q1 2019, $2.2 million in Q4 2018, and $9000.0 in Q3 2018.